Endocrine Abstracts

Introduction: The data on giant prolactinomas (the rare (3%) subtype of lactotroph PitNET (≥40 mm) ), often causing clinical and therapeutic difficulties are scarce.Aim: We studied clinical/biochemical and treatment outcomes differences between giant and macroprolactinomas.Materials and methods: Consecutive patients with giant prolactinomas ≥40 mm (GP) and macroprolactinomas >10 mm<40 mm (MP) treated in the tert...

A global TC risk in a single thyroid nodule is rather small and ranges between 1 and 11%. However, taking into consideration Bethesda System for Reporting Thyroid Cytopathology TC risk varies between distinct categories: 0–3, 5–15, 15–30, 60–75 and 97–99% for Bethesda class II–VI, respectively. However, these values may differ in a centre, specialized in TC. Therefore, the aim of this study was to evaluate the TC risk in patients referred to a ter...

Background: Differentiated thyroid carcinoma (DTC) in children is a rare cancer, occurring in 1/100,000 children/year. In the adults a steady increase in the incidence and change in presentation of DTC has been observed over the past 30 years.Purpose: Evaluation of changes in the clinical presentation of paediatric DTC on the example of children treated in Institute of Oncology in Gliwice between 1970 and 2015.Material and methods:...

Introduction: Ectopic Cushing’s syndrome (ECS) is a rare disease with limited and error-prone published data on the epidemiology, clinical presentation and diagnosis of ECS.Objectives: This study aims to examine the clinical course of patients with ECS in relation to the primary tumor localization.Methods: Thirty-five consecutive ECS patients at a tertiary clinical center were analyzed. The clinical, biochemical (including CRH...

Paltusotine is a once-daily, oral selective nonpeptide somatostatin receptor type 2 (SST2) agonist, which is in clinical development for the treatment of acromegaly. Maintenance of insulin-like growth factor 1 (IGF-1) control and toleration was demonstrated in phase 2 studies evaluating paltusotine in biochemically controlled (IGF-1 ≤1xULN) [ACROBAT Evolve (NCT03792555)] and uncontrolled (1> IGF-1 ≤2.5xULN) [ACROBAT Edge (NCT03789656)] patients with acromegaly ...

The aim of this study was to evaluate in a long follow-up time patients with acromegaly successfully treated by transphenoidal surgery (TNS) in order to establish the recurrence rate and the need of subsequent follow up.Methods: We retrospectively analyzed data of 283 acromegalic patients (168 females, mean age: 44.2 ±12.9 years) who underwent TNS for a GH secreting pituitary adenoma between 1980 and 2020, on regular follow-up at two Pituitary Units...

Paltusotine is a once-daily, oral, nonpeptide somatostatin receptor type 2 (SST2) specific agonist, in development for the treatment of acromegaly and neuroendocrine tumors. We report interim results from ACROBAT Advance (NCT04261712), an ongoing, multicenter, open-label, long-term extension study of paltusotine in subjects with acromegaly who previously completed either Phase 2 study ACROBAT Edge (NCT03789656) or Evolve (NCT03792555). ACROBAT Edge enrolled 47 subjects with el...

Background: Invasive nonfunctioning (NF) pituitary neuroendocrine tumors (PitNETs) are non-resectable neoplasms associated to frequent relapse and significant comorbidities. As current treatments often fail against NF-PitNETs, identifying actionable therapeutic targets is essential. We focused on the angiopoietin-2 (Angpt2)/Tie2 axis, usually active in endothelial cells (ECs).Methods: ANGPT2 plasma levels in NF-PitNET patients and healthy controls were m...

Background: Molecular analysis of thyroid fine-needle aspiration biopsy (FNA) was proposed to improve indeterminate nodules management. However, sensibility and specificity as well as the cost of molecular diagnostics require to be improved to increase their cost-effectiveness for medical practice setting. Raman spectroscopy (RS) demonstrated ability in separating benign from malignant thyroid lesions in surgically removed tissues, based on specific RS profile. This study aime...

Introduction: Differentiated thyroid cancers (DTCs) carrying BRAF and TERT mutations are associated with high-risk clinicopathological features and poor prognosis. However, there are currently no studies comparing BRAF-TERT tumors to other double mutated DTCs.Aim: To verify whether BRAF-TERT mutated DTCs differ from other double mutated DTCs in terms of clinicopathological characteristics and outcome.Materials and Methods: 168 DTCs...